Cambridge biotech Moderna said it will ask federal regulators Monday to authorize emergency use of its experimental COVID-19 vaccine, after complete results from a late-stage study showed the substance was 94.1 percent effective at preventing the disease and 100 percent effective at warding off severe cases.
The final efficacy results from a clinical trial of 30,000 volunteers were almost identical to an interim analysis released by the company two weeks ago. The latest data set the stage for the possibility that at least two vaccines will be available on a limited basis in the US by the end of the year.
Read the full story on BostonGlobe.com.
Previously:
Pfizer asks FDA for emergency use of COVID-19 vaccine
|
|
SPECIAL OFFER
To mark Black Friday and Cyber Monday, BostonGlobe.com has a remarkable deal for new subscribers: Six months (26 weeks) of access to the entire Globe online for just $1. Not $1 a week; $1 for all 26 weeks. The offer is good through Monday, and again, it’s for new subscribers only.
You can sign up here.
|
|
|
|
|
|
We have lots of e-mail newsletters on a variety of topics, including news, politics, business, sports, lifestyle, and more. They're free, and it's easy to subscribe. Here's a complete list.
|
|
|
|
